moxifloxacin has been researched along with 2-cyclopentyl-2-hydroxy-2-phenylacetic acid (1,1-dimethyl-3-pyrrolidin-1-iumyl) ester in 1 studies
| Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (2-cyclopentyl-2-hydroxy-2-phenylacetic acid (1,1-dimethyl-3-pyrrolidin-1-iumyl) ester) | Trials (2-cyclopentyl-2-hydroxy-2-phenylacetic acid (1,1-dimethyl-3-pyrrolidin-1-iumyl) ester) | Recent Studies (post-2010) (2-cyclopentyl-2-hydroxy-2-phenylacetic acid (1,1-dimethyl-3-pyrrolidin-1-iumyl) ester) |
|---|---|---|---|---|---|
| 3,157 | 552 | 1,690 | 5 | 0 | 4 |
| Protein | Taxonomy | moxifloxacin (IC50) | 2-cyclopentyl-2-hydroxy-2-phenylacetic acid (1,1-dimethyl-3-pyrrolidin-1-iumyl) ester (IC50) |
|---|---|---|---|
| Testosterone 17-beta-dehydrogenase 3 | Rattus norvegicus (Norway rat) | 0.0001 | |
| Muscarinic acetylcholine receptor M2 | Homo sapiens (human) | 0.0002 | |
| Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | 0.0002 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for moxifloxacin and 2-cyclopentyl-2-hydroxy-2-phenylacetic acid (1,1-dimethyl-3-pyrrolidin-1-iumyl) ester
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |